EN
/
FR
Ethics Portal
Who We Are
Who We Are
About Us
Business Model
Our Strategy 2023-2025
Statutes, By-Laws & Policies
Governance & Team
Annual Reports
Careers & RFPs
What We Do
What We Do
Licensing for Public Health
mRNA Technology Transfer Programme
Disease Areas
Addressing Children’s Needs
Prioritising Medicines for Licensing
Long-Acting Therapeutics
Focus areas
Biotherapeutics
Local and Regional Manufacturing
Pandemic Preparedness and Response
Upstream Access
Technology Transfer
Patent Information Tools
MedsPaL
LAPaL
Progress and Impact
Progress
and Impact
Prioritisation
Agreements with Innovators
Access to Medicines Tracker
Contribution to Universal Health Coverage
Endorsements
Impact
News & Publications
News
& Publications
News, Events & Press Releases
Messages from the Executive Director
MPP in the Media
MPP Publications
Related Publications
Newsletters & Updates
Partners
Partners
Partnering with MPP
Funders
Our Stories
Voices from Friends of MPP
Voices from the Frontline
I am part of the DTG story
How to Give or Get a Licence
Contact Us
EN
/
FR
Ethics Portal
Our
Projects
MRNA Technology Transfer Programme
VaxPaL
News & Press Releases » News
MPP welcomes WHO announcement of the first COVID-19 mRNA vaccine...
Geneva – The Medicines Patent Pool (MPP) welcomes the World Health Organization’s (WHO) announcement of...
News & Press Releases » Press Releases
The Medicines Patent Pool (MPP) and MSD enter into licence...
MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of molnupiravir under...
News & Press Releases » Press Releases
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement...
Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and...
COVID-19 Open Pledge
MPP and COVID-19
Overview
COVID-19